Schedule 2 Amendment to Annex 6
“
33 1,1’-(1,4-piperazinediyl)bis[1-[2-[4-(diethylamino)-2-hydroxybenzoyl]phenyl]-methanone Bis-(Diethylaminohydroxybenzoyl Benzoyl) Piperazine 919803-06-8 485-100-6 10% In case of combined use of Bis-(Diethylaminohydroxybenzoyl Benzoyl) Piperazine and Bis-(Diethylaminohydroxybenzoyl Benzoyl) Piperazine (nano), the sum shall not exceed 10 %. Not to be used in applications that may lead to exposure of the end user’s lungs by inhalation. 34 1,1’-(1,4-piperazinediyl)bis[1-[2-[4-(diethylamino)-2-hydroxybenzoyl]phenyl]-methanone Bis-(Diethylaminohydroxybenzoyl Benzoyl) Piperazine (nano) 919803-06-8 485-100-6 10% Only nanomaterials having the following characteristics are allowed:
Purity ≥ 97 %,
Median particle size D50 (50 % of the number below this diameter): ≥ 50 nm of number size distribution.
Not to be used in applications that may lead to exposure of the end user’s lungs by inhalation. In case of combined use of Bis-(Diethylaminohydroxybenzoyl Benzoyl) Piperazine and Bis-(Diethylaminohydroxybenzoyl Benzoyl) Piperazine (nano), the sum shall not exceed 10 %. ”